Fig. 4From: Improved synthesis of [18F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptorsNo mass effect to BPND of [18F] fallypride was observed when using high specific activity (MA > 100 GBq/μmol) at the time of injection. Line represents linear regression of the populationBack to article page